A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth

IUBMB Life

Volumn 64, Issue 9, 2012, Pages 757-765

  Qiu, Yuhe ^a   Zhang, Zhixin ^b   Shi, Juan ^a   Liu, Shilian ^a   Liu, Yanxin ^a   Zheng, Dexian ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b Beijing Red Cross Blood Center   (China)

Author keywords

anti DR5 chimeric antibody; combination therapy; DR5; epirubicin

Indexed keywords

CHIMERIC ANTIBODY; CHIMERIC ANTIBODY HMCAZ 5; DEATH RECEPTOR 5; EPIRUBICIN; FLICE INHIBITORY PROTEIN; JANUS KINASE; PROTEIN BID; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CHO CELL; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; RECEPTOR AFFINITY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; DRUG SYNERGISM; EPIRUBICIN; FEMALE; HUMANS; KIDNEY; LIVER; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865335607     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.1064     Document Type: Article

References (26)

1. Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., et al. (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682. (Pubitemid 26091143)
2. Ashkenazi, A., (2002) Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat. Rev. Cancer 2, 420-430. (Pubitemid 37328939)
3. Gliniak, B., Le, T., (1999) Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res. 59, 6153-6158. (Pubitemid 30035636)
4. Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., et al. (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7, 954-960. (Pubitemid 32756434)
5. Forero-Torres, A., Shah, J., Wood, T, Posey, J, Carlisle, R,. et al. (2010) Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother. Radiopharm. 25, 13-19.
6. Camidge, D. R., Herbst, R. S., Gordon, M. S., Eckhardt, S. G., Kurzrock, R., et al. (2010) A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin. Cancer Res. 16, 1256-1263.
7. Guo, Y., Chen, C., Zheng, Y., Zhang, J., Tao, X., et al. (2005) A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J. Biol. Chem. 280, 41940-41952. (Pubitemid 43023163)
8. Zhang, P., Zheng, Y., Shi, J., Zhang, Y., Liu, S., et al. (2010) Targeting a novel N-terminal epitope of death receptor 5 triggers tumor cell death. J. Biol. Chem. 285, 8953-8966.
9. Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., et al. (2003) Complement activation determines the therapeutic activity of rituximab in vivo. Cancer J. Immunol. 171, 1581-1587. (Pubitemid 36900094)
10. Natsume, A., Niwa, R., and, Satoh, M., (2009) Improving effector functions of antibodies for cancer treatment: enhancing ADCC and CDC. Drug Des. Dev. Ther. 3, 7-16.
11. Voelkel-Johnson, C., King, D. L., and, Norris, J. S., (2002) Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 9, 164-172. (Pubitemid 34141919)
12. Fang, J., Qian, J. J., Yi, S., Harding, T. C., Tu, G. H., et al. (2005) Stable antibody expression at therapeutic levels using the 2A peptide. Nat. Biotechnol. 23, 584-590. (Pubitemid 41724897)
13. Kim, Y., Suh, N., Sporn, M., and, Reed, J. C., (2002) An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem. 277, 22320-22329. (Pubitemid 34967199)
14. Li, H., Zhu, H., Xu, C. J., and, Yuan, J., (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491-501. (Pubitemid 28391865)
15. Dhanasekaran, D. N., and, Reddy, E. P., (2008) JNK signaling in apoptosis. Oncogene 27, 6245-6251.
16. Aikin, R., Maysinger, D., and, Rosenberg, L., (2004) Cross-talk between phosphatidylinositol 3-kinase/AKT and c-Jun NH2-terminal kinase mediates survival of isolated human islets. Endocrinology 145, 4522-4531. (Pubitemid 39281444)
17. Motoki, K., Mori, E., Matsumoto, A., Thomas, M., Tomura, T., et al. (2005) Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin. Cancer Res. 11, 3126-3135. (Pubitemid 40525220)
18. Carter, P. J., (2006) Potent antibody therapeutics by design. Nat. Rev. Immunol. 6, 343-357.
19. Cacciatore, J. J., Chasin, L. A., and, Leonard, E. F., (2010) Gene amplification and vector engineering to achieve rapid and high-level therapeutic protein production using the Dhfr-based CHO cell selection system. Biotechnol. Adv. 28, 673-681.
20. Strome, S. E., Sausville, E. A., and, Mann, D., (2007) A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist 12, 1084-1095. (Pubitemid 350007020)
21. Wang, S., Ren, W., Liu, J., Lahat, G., Torres, K., et al. (2010) TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin. Cancer Res. 16, 2591-2604.
22. Kim, D. S., Kim, H. R., Woo, E. R., Hong, S. T., Chae, H. J., et al. (2005) Inhibitory effects of rosmarinic acid on adriamycin-induced apoptosis in H9c2 cardiac muscle cells by inhibiting reactive oxygen species and the activations of c-Jun N-terminal kinase and extracellular signal-regulated kinase. Biochem. Pharmacol. 70, 1066-1078.
23. Ohtsuka, T., Buchsbaum, D., Oliver, P., Makhija, S., Kimberly, R., et al. (2003) Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22, 2034-2044. (Pubitemid 36523640)
24. Shan, Y. X., Liu, T. J., Su, H. F., Samsamshariat, A., Mestril, R., et al. (2003) Hsp10 and Hsp60 modulate Bcl-2 family and mitochondria apoptosis signaling induced by doxorubicin in cardiac muscle cells. J. Mol. Cell. Cardiol. 35, 1135-1143. (Pubitemid 37083257)
25. Jain, K. K., Casper, E. S., Geller, N. L., Hakes, T. B., Kaufman, R. J., et al. (1985) A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J. Clin. Oncol. 3, 818-826. (Pubitemid 15062910)
26. Ryberg, M., Nielsen, D., Cortese, G., Nielsen, G., Skovsgaard, T., et al. (2008) New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J. Natl. Cancer Inst. 100, 1058-1067.